• 미생물학회지
• /
• 제25권3호
• /
• pp.165-172
• /
• 1987

An expression vector in a mammalian cell was constructed using the origin of replication (OR) and the promoters of SV40. The plasmid pSVOE was constructed by inserting SV40 DNA fragment (1, 118bp) containing SV40 OR and promoters into pBR322-1, and then a multiple cloning sequence was inserted at the immediate downstream of the late promoter of SV40 in the pSVOE vector. The plasmid was named pSVML. As a selection marker, thymidine kinase gene of herpes simplex virus with its promoter was inserted into EcoRI site of pSVML and the recombinant was named pSVML-TKp. To test the expression capacity of foreigen gene inserted at the multiple cloning site of pSVML, the thymidine kinase gene without its own promoter was inserted at the BamHI site of pSVML. The recombinant was named pSVML-TK. These plasmids, pSVML-TKp and pSVML-TK, were transfected into COS cells with calcium phosphate precipitation method. The thymidine kinase activity was significantly increased in both transfected cells.

• Clinical and Experimental Pediatrics
• /
• 제46권4호
• /
• pp.335-339
• /
• 2003

목 적 : 폐 표면 활성제 단백질-A는 폐 표면 활성제의 생리작용과 구조에 관여하며, 폐의 숙주방어와 염증반응에 주된 역할을 하고 있다. 스테로이드 치료는 미숙아의 분만이 예측되는 산모에 대해서 미숙아의 급성 호흡곤란 증후군 등을 예방할 목적으로, 또는 미숙아의 만성 폐질환을 예방하기 위하여 널리 사용되고 있다. 현재까지 인간에서 두 가지의 SP-A 유전자 및 여러 종류의 대립형질이 밝혀져 있고, 덱사메타손 치료에 서로 다른 반응을 보이고 있으며, SP-A 3'UTR이 관여 할 가능성이 있다는 연구가 발표되었다. 저자들은 가장 많은 빈도를 보이는 8가지 SP-A 대립형질에서 덱사메타손 처치에 대하여 서로 다른 반응이 3'UTR에 의하여 이루어지는지를 규명하고자 연구를 하였다. 방 법 : 리포터 유전자로서 luciferase를 사용하여 8종류의 SP-A 대립형질의 3'UTR을 포함하는 구성체를 만들었다. 이 구성체들은 SV40 promotor에 의하여 조절되었으며, SP-A를 생산하는 H441 세포내로 형질도입 되었다. 덱사메타손 처치 후 리포터 유전자의 활성도를 측정하였으며, 대조군에 따라 표준화되었다. 결 과 : 덱사메타손 처치 시 $6A^3$, 6A, 1A 대립 유전자에서 리포터 유전자의 활성 반응이 유의하게 감소하였다. 결 론 : SP-A 유전자 변이 중 덱사메타손 처치에 대한 유전자 표현 반응이 서로 다르다는 사실은 스테로이드 치료 시 미숙아의 개개인의 SP-A 유전자 변이에 따라 고려하여 사용해야함이 타당할 것으로 생각된다.

• 한국잠사곤충학회지
• /
• 제40권1호
• /
• pp.52-59
• /
• 1998

For the construction of plasmid and bmNPV sarrying the FRT recognition site for the FLP recombinases, we synthesized the wild type FRT dligonucleotides. The target FRT sequences consist of three 13bp repeated DNA sequences; two repeats in a direct orientation and one inverted relative to the other two. In addition, there is an 8bp spacer region between the repeats which determune the orientation of the FRT recombination site. In order to place the FRT site both in target BmNPV genome and the transfer vector, we constructed a plasmid, FRT site both in the target BmNPv genome and the transfer vector, we constructed a plasmid, pFRT$\beta$-gal, carrying the FRT sites within the cloning sites of pSV vector and a recombinant BmNPV, vFRTPH, carrying the FRT sites at a downstream of polyhedrin promotor, respectively. In order to test the functionality of the FLP/FRT site-specific recombination system, vFRTPH, pFRT$\beta$-gal and pHsFLP DNA were co-transfected into BmN-4 cells. The resulting recombinant virus was designated a vFRT$\beta$2-gal. From construction analysis of the vFRT$\beta$2-gal with PCR technique it was concluded that the entire pFRT$\beta$-gal plasmid with $\beta$-galactosidase gene and origines of replication flanked by two functional hybrid FRT sequences. The efficiency of recombination was 8.7%, which was higher than that(2.2%) of recombination between a conventional transfer vector and the wild type BmNPV.